Recent Advances in Cancer Immunotherapy: Clinical Implications and Future Directions

References (28)

1. 1 The clinical progress of mRNA vaccines and immunotherapies [DOI]
2. 2 CAR T cells in solid tumors: challenges and opportunities [DOI]
3. 3 Opportunities and Challenges in the Delivery of mRNA-Based Vaccines [DOI]
4. 4 CD40 Agonist Antibodies in Cancer Immunotherapy [DOI]
5. 5 Intratumoural administration and tumour tissue targeting of cancer immunotherapies [DOI]
6. 6 Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners [DOI]
7. 7 Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy [DOI]
8. 8 Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier [DOI]
9. 9 A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization [DOI]
10. 10 Interleukin-1 as Innate Mediator of T Cell Immunity [DOI]
11. 11 CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments [DOI]
12. 12 CAR-T cell combination therapy: the next revolution in cancer treatment [DOI]
13. 13 mRNA cancer vaccines: Advances, trends and challenges [DOI]
14. 14 DC-Based Vaccines for Cancer Immunotherapy [DOI]
15. 15 Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice [DOI]
16. 16 Tumor Cell-Based Vaccine: An Effective Strategy for Eradication of Cancer Cells [DOI]
17. 17 Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials [DOI]
18. 18 Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies [DOI]
19. 19 Cancer immunotherapy: a promising dawn in cancer research.
20. 20 Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity [DOI]
21. 21 Oncolytic Vaccinia Virus in Lung Cancer Vaccines [DOI]
22. 22 Recent Advances in Cancer Immunotherapy Delivery Modalities [DOI]
23. 23 Biomaterials for enhanced immunotherapy [DOI]
24. 24 Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy [DOI]
25. 25 Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis [DOI]
26. 26 Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response [DOI]
27. 27 Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment [DOI]
28. 28 Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer [DOI]

Cited by 0

No indexed citations yet.

Related research

• Advancing Glioblastoma Treatment: Challenges and Opportunities of Immune Checkpoint Inhibition — shares topic coverage
• Accessibility and Inclusivity of Chimeric Antigen Receptor T-cell Immunotherapy in Treating Hematological Malignancies — shares topic coverage
• Immune-Related Adverse Events of Checkpoint Inhibitors: Clinical Spectrum and Insights Across Major Malignancies — shares topic coverage
• Immunotherapy Strategies for Overcoming Resistant Cancers: Current Trends and Future Prospects — shares topic coverage
• Targeted and Immunotherapeutic Approaches in Cancer: A Narrative Review of Evolving Evidence and Clinical Implications — shares topic coverage